| academic journal | Q737498 |
| scientific journal | Q5633421 |
| open-access journal | Q773668 |
| P6981 | ACNP journal ID | 2981666 |
| P8375 | Crossref journal ID | 86987 |
| 218830 | ||
| P5115 | Directory of Open Access Journals ID | 2090-0252 |
| 2090-8024 | ||
| P1058 | ERA Journal ID | 200673 |
| P8903 | HAL journal ID | 62797 |
| P236 | ISSN | 2090-0252 |
| 2090-8024 | ||
| P7363 | ISSN-L | 2090-0252 |
| P1277 | JUFO ID | 70645 |
| P4730 | Mir@bel journal ID | 14575 |
| P1055 | NLM Unique ID | 101525141 |
| P856 | official website | https://www.hindawi.com/journals/ijad/ |
| P10283 | OpenAlex ID | V147542015 |
| P3181 | OpenCitations bibliographic resource ID | 81609 |
| P8104 | Paperity journal ID | 413319 |
| P12834 | PMC journal ID | 1289 |
| P7662 | Scilit journal ID | 2205756 |
| P1156 | Scopus source ID | 19700177306 |
| P166 | award received | DOAJ seal | Q73548471 |
| P972 | catalog | Directory of Open Access Journals | Q1227538 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P17 | country | United Kingdom | Q145 |
| P495 | country of origin | United Kingdom | Q145 |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neuropsychiatry | Q2699874 | ||
| P123 | publisher | Hindawi Publishing Corporation | Q1619253 |
| P1476 | title | International journal of Alzheimer's disease |
| Q46656414 | A Pilot Study of the Impact of NHS Patient Transportation on Older People with Dementia. |
| Q42247119 | A changing perspective on the role of neuroinflammation in Alzheimer's disease |
| Q38368071 | A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death |
| Q34495325 | A factor analytic approach to symptom patterns in dementia |
| Q35029787 | A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the italian population do not support a large effect on Alzheimer's disease risk |
| Q33747249 | A research on functional status, environmental conditions, and risk of falls in dementia |
| Q35810543 | A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease |
| Q42147254 | A unifying hypothesis for familial and sporadic Alzheimer's disease |
| Q36340308 | A warning index used in prescreening for Alzheimer's disease, based on self-reported cognitive deficits and vascular risk factors for dementia in elderly patients with type 2 diabetes |
| Q34109343 | AICD Overexpression in Neuro 2A Cells Regulates Expression of PTCH1 and TRPC5 |
| Q41988079 | Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. |
| Q40796484 | Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model |
| Q41848725 | Acetylcholinesterase inhibitors promote angiogenesis in chick chorioallantoic membrane and inhibit apoptosis of endothelial cells |
| Q36238879 | Adaptive walking in Alzheimer's disease. |
| Q42738860 | Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment |
| Q42269090 | Affective learning and psychophysiological reactivity in dementia patients. |
| Q37224663 | Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation |
| Q35993891 | Alterations in Lipid Levels of Mitochondrial Membranes Induced by Amyloid-β: A Protective Role of Melatonin |
| Q33736357 | Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of disease |
| Q42176144 | Alternative strategy for Alzheimer's disease: stress response triggers |
| Q63976703 | Alzheimer's Disease Frontal Cortex Mitochondria Show a Loss of Individual Respiratory Proteins but Preservation of Respiratory Supercomplexes |
| Q60958549 | Alzheimer's Disease Mortality according to Socioeconomic Factors: Country Study |
| Q35664117 | Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System |
| Q26776157 | Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment |
| Q41825866 | Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease |
| Q34725385 | Alzheimer's disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling |
| Q35855587 | Alzheimer's disease and the amyloid cascade hypothesis: a critical review |
| Q36111324 | Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience |
| Q35094369 | Alzheimer's disease genes are associated with measures of cognitive ageing in the lothian birth cohorts of 1921 and 1936 |
| Q42028225 | Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. |
| Q34127614 | Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease |
| Q30157432 | Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification |
| Q42281747 | Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy |
| Q28742804 | Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts |
| Q90405196 | Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42 |
| Q46656288 | Amyloid-Beta Peptide, Oxidative Stress and Inflammation in Alzheimer's Disease: Potential Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids. |
| Q34725635 | Amyloid-Beta interaction with mitochondria |
| Q34442793 | An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome |
| Q33970004 | An unusual cause of dementia: essential diagnostic elements of corticobasal degeneration-a case report and review of the literature |
| Q55118096 | Analysis of Association of Genetic Markers in the LUZP2 and FBXO40 Genes with the Normal Variability in Cognitive Performance in the Elderly. |
| Q34223702 | Analyzing microarray data of Alzheimer's using cluster analysis to identify the biomarker genes |
| Q42020891 | Animal models of Alzheimer's disease |
| Q41998948 | Anticholinesterase and Antioxidative Properties of Aqueous Extract of Cola acuminata Seed In Vitro. |
| Q34591124 | ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function |
| Q42247507 | Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade |
| Q34077530 | Applying New Research Criteria for Diagnosis of Early Alzheimer's Disease: Sex and Intelligence Matter |
| Q41982613 | Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment? |
| Q35224843 | Assessing the sociocultural impacts of emerging molecular technologies for the early diagnosis of Alzheimer's disease |
| Q37548064 | Assessment of Health-Related Quality of Life for Caregivers of Alzheimer's Disease Patients. |
| Q42729002 | Association Study of Genetic Variants in CDKN2A/CDKN2B Genes/Loci with Late-Onset Alzheimer's Disease |
| Q48213918 | Association between the APOE ε4 Allele and Late-Onset Alzheimer's Disease in an Ecuadorian Mestizo Population |
| Q42791835 | Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease |
| Q42409935 | Auditory and Visual Cues for Topic Maintenance with Persons Who Exhibit Dementia of Alzheimer's Type |
| Q35846002 | Automated VOI Analysis in FDDNP PET Using Structural Warping: Validation through Classification of Alzheimer's Disease Patients |
| Q35094356 | Aβ behavior on neuronal membranes: aggregation and toxicities. |
| Q42620803 | Aβ internalization by neurons and glia |
| Q34245025 | Behavioral impact of the regulation of the brain 2-oxoglutarate dehydrogenase complex by synthetic phosphonate analog of 2-oxoglutarate: implications into the role of the complex in neurodegenerative diseases |
| Q42014552 | Beneficial Effects of Teucrium polium and Metformin on Diabetes-Induced Memory Impairments and Brain Tissue Oxidative Damage in Rats. |
| Q35030142 | Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice |
| Q42728923 | Bioinformatics identification of modules of transcription factor binding sites in Alzheimer's disease-related genes by in silico promoter analysis and microarrays |
| Q34089784 | Biological markers and Alzheimer disease: a canadian perspective |
| Q35504167 | Biomarkers for microglial activation in Alzheimer's disease |
| Q41849805 | Biomarkers in Alzheimer's disease and lewy body disorders with dementia. |
| Q34442605 | Biomarkers of Alzheimer's disease: from central nervous system to periphery? |
| Q35030049 | Biomarkers of the dementia. |
| Q35417970 | Biomarkers to measure treatment effects in Alzheimer's disease: what should we look for? |
| Q42124171 | Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring |
| Q34496928 | Brain imaging of nicotinic receptors in Alzheimer's disease |
| Q35094391 | Bridging molecular genetics and biomarkers in lewy body and related disorders |
| Q35606762 | Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease |
| Q41860053 | Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze. |
| Q42091274 | CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder. |
| Q41897818 | CSF Biomarkers for Alzheimer's Disease Diagnosis |
| Q35130936 | Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementia |
| Q42835594 | Capacity to vote in persons with dementia and the elderly |
| Q37283502 | Cardiovascular risk and hippocampal thickness in Alzheimer's disease |
| Q36845117 | Care for Alzheimer's disease |
| Q42061214 | Caspase-mediated truncation of tau potentiates aggregation |
| Q34572746 | Cell surface binding and internalization of aβ modulated by degree of aggregation |
| Q35001126 | Centella asiatica Attenuates D-Galactose-Induced Cognitive Impairment, Oxidative and Mitochondrial Dysfunction in Mice |
| Q35810705 | Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. |
| Q34460818 | Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP and APP/PS1 Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration? |
| Q38585712 | Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates |
| Q34026659 | Cerebrospinal fluid analysis should be considered in patients with cognitive problems |
| Q34248241 | Cerebrospinal fluid biomarkers for dementia with lewy bodies |
| Q42062882 | Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus |
| Q34460631 | Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease |
| Q36077153 | Characterizing cognitive deficits and dementia in an aging urban population in India |
| Q30521276 | Chinese-language montreal cognitive assessment for cantonese or mandarin speakers: age, education, and gender effects |
| Q34373769 | Cholesterol and copper affect learning and memory in the rabbit. |
| Q42573764 | Choline modulation of the aβ p1-40 channel reconstituted into a model lipid membrane. |
| Q34442660 | Chronic cerebral ischaemia forms new cholinergic mechanisms of learning and memory |
| Q34127734 | Circadian rhythm disturbances in patients with Alzheimer's disease: a review |
| Q34042453 | Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease. |
| Q92065355 | Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy |
| Q42126067 | Clinical neurophysiology in Alzheimer's disease |
| Q37245297 | Clinical trial of a home safety toolkit for Alzheimer's disease |
| Q90601008 | Cognitive Assessment Test: Validation of a Short Cognitive Test for the Detection of Mild Cognitive Disorder |
| Q30524309 | Cognitive deterioration and associated pathology induced by chronic low-level aluminum ingestion in a translational rat model provides an explanation of Alzheimer's disease, tests for susceptibility and avenues for treatment |
| Q34465488 | Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach |
| Q35169622 | Cognitive stimulation programs in healthy elderly: a review |
| Q34123736 | Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia |
| Q42738261 | Combining transcranial magnetic stimulation and electroencephalography may contribute to assess the severity of Alzheimer's disease |
| Q41785626 | Comparative Neuroprotective Effects of Dietary Curcumin and Solid Lipid Curcumin Particles in Cultured Mouse Neuroblastoma Cells after Exposure to Aβ42 |
| Q37330079 | Comparing Cognitive Profiles of Licensed Drivers with Mild Alzheimer's Disease and Mild Dementia with Lewy Bodies. |
| Q35240139 | Comparison of Vascular Perturbations in an Aβ-Injected Animal Model and in AD Brain |
| Q42055242 | Comparison of the inhibition of monoamine oxidase and butyrylcholinesterase activities by infusions from green tea and some citrus peels |
| Q34381556 | Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's disease |
| Q34078408 | Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid |
| Q42684539 | Conjugated Quantum Dots Inhibit the Amyloid β (1-42) Fibrillation Process |
| Q35418836 | Copper Inhibits NMDA Receptor-Independent LTP and Modulates the Paired-Pulse Ratio after LTP in Mouse Hippocampal Slices |
| Q35184353 | Copper modulation as a therapy for Alzheimer's disease? |
| Q41784215 | Copper status in Alzheimer's disease and other neurodegenerative disorders 2013. |
| Q40008019 | Copper status in Alzheimer's disease and other neurodegenerative disorders: genetics, mechanisms, neurophysiology, and therapies |
| Q34479110 | Correlation of copper interaction, copper-driven aggregation, and copper-driven h(2)o(2) formation with aβ40 conformation |
| Q42363008 | Corrigendum to "Alzheimer's Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience". |
| Q37600459 | Cost effective community based dementia screening: a markov model simulation. |
| Q37212536 | Cumulative effect of depression on dementia risk |
| Q42135408 | Deconstructing GSK-3: The Fine Regulation of Its Activity |
| Q37283515 | Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction |
| Q37632067 | Dementia Coding, Workup, and Treatment in the VA New England Healthcare System. |
| Q36021657 | Dementia and diabetes mellitus: association with apolipoprotein e4 polymorphism from a hospital in southern India. |
| Q37960496 | Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease |
| Q46656626 | Development and Psychometric Validation of the Dementia Attitudes Scale. |
| Q58573706 | Development of Regional Disparities in Alzheimer's Disease Mortality in the Slovak Republic from 1996 to 2015 |
| Q40310487 | Diagnostic Accuracy of the Overlapping Infinity Loops, Wire Cube, and Clock Drawing Tests for Cognitive Impairment in Mild Cognitive Impairment and Dementia. |
| Q34089759 | Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges |
| Q35606785 | Diagnostic Utility of CSF Tau and Aβ(42) in Dementia: A Meta-Analysis |
| Q35903978 | Dietary Cholesterol Concentration and Duration Degrade Long-Term Memory of Classical Conditioning of the Rabbit's Nictitating Membrane Response |
| Q34043551 | Differential network analyses of Alzheimer's disease identify early events in Alzheimer's disease pathology |
| Q34923220 | Direction of Information Flow in Alzheimer's Disease and MCI Patients |
| Q28254726 | Disturbed copper bioavailability in Alzheimer's disease |
| Q42738296 | Does EEG montage influence Alzheimer's disease electroclinic diagnosis? |
| Q46656746 | Down's Syndrome with Alzheimer's Disease-Like Pathology: What Can It Teach Us about the Amyloid Cascade Hypothesis? |
| Q36374569 | Driving Competence in Mild Dementia with Lewy Bodies: In Search of Cognitive Predictors Using Driving Simulation |
| Q36026426 | Drosophila models of tauopathies: what have we learned? |
| Q34176659 | Drug utilization pattern in patients with different types of dementia in Western India |
| Q41983258 | E22Δ Mutation in Amyloid β-Protein Promotes β-Sheet Transformation, Radical Production, and Synaptotoxicity, But Not Neurotoxicity. |
| Q48246714 | Early Contextual Fear Memory Deficits in a Double-Transgenic Amyloid-β Precursor Protein/Presenilin 2 Mouse Model of Alzheimer's Disease |
| Q34159350 | Early Detection of Brain Pathology Suggestive of Early AD Using Objective Evaluation of FDG-PET Scans |
| Q39115427 | Early clinical and molecular detection of Alzheimer's disease |
| Q42573332 | Effect of Metal Chelators on γ-Secretase Indicates That Calcium and Magnesium Ions Facilitate Cleavage of Alzheimer Amyloid Precursor Substrate |
| Q37960499 | Effect of transcranial brain stimulation for the treatment of Alzheimer disease: a review |
| Q28391507 | Effects of Copper and/or Cholesterol Overload on Mitochondrial Function in a Rat Model of Incipient Neurodegeneration |
| Q35829665 | Effects of anosognosia on perceived stress and cortisol levels in Alzheimer's disease |
| Q41924531 | Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia |
| Q30422220 | Efficacy of music therapy in treatment for the patients with Alzheimer's disease |
| Q38215516 | Electroencephalogram and Alzheimer's disease: clinical and research approaches |
| Q37883098 | Electroencephalographic rhythms in Alzheimer's disease |
| Q42728668 | Electromyographic activity in the EEG in Alzheimer's disease: noise or signal? |
| Q36328894 | Elevated angiopoietin-1 serum levels in patients with Alzheimer's disease |
| Q42583034 | Emotion processing for arousal and neutral content in Alzheimer's disease |
| Q30441685 | Emotional working memory and Alzheimer's disease |
| Q31154141 | Enhancing Diagnostic Accuracy of aMCI in the Elderly: Combination of Olfactory Test, Pupillary Response Test, BDNF Plasma Level, and APOE Genotype |
| Q30207543 | Enhancing resourcefulness to improve outcomes in family caregivers and persons with Alzheimer's disease: a pilot randomized trial |
| Q34079841 | Epidemiology of Dementia among the Elderly in Sub-Saharan Africa |
| Q41807075 | Erratum: gene-environment interaction research and transgenic mouse models of Alzheimer's disease. |
| Q38975941 | Evaluating Adult's Competency: Application of the Competency Assessment Process |
| Q35113702 | Evaluating voting competence in persons with Alzheimer disease |
| Q34042253 | Evaluation of BACE1 Silencing in Cellular Models |
| Q39491442 | Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia |
| Q36014695 | Executive Dysfunction in MCI: Subtype or Early Symptom |
| Q37273728 | Expression of Phenotypic Astrocyte Marker Is Increased in a Transgenic Mouse Model of Alzheimer's Disease versus Age-Matched Controls: A Presymptomatic Stage Study. |
| Q37060648 | Family Dynamics and Personal Strengths among Dementia Caregivers in Argentina |
| Q30416305 | Family composition and expressions of family-focused care needs at an academic memory disorders clinic |
| Q35030392 | Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid |
| Q34552387 | Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps |
| Q42116198 | Fluorescent analysis of the cell-selective Alzheimer's disease aβ Peptide surface membrane binding: influence of membrane components |
| Q34557414 | Formation of Toxic Amyloid Fibrils by Amyloid β-Protein on Ganglioside Clusters |
| Q38037524 | Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases |
| Q34951817 | Function and comorbidities of apolipoprotein e in Alzheimer's disease |
| Q41096092 | Functional analytic multisensory environmental therapy for people with dementia |
| Q37903257 | Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation |
| Q35001040 | GSK-3 in Neurodegenerative Diseases. |
| Q42748129 | GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration |
| Q36302652 | Gender differences in dementia spousal caregiving. |
| Q35418674 | Gender effects on plasma and brain copper |
| Q34240443 | Gender-Specific Neuroimmunoendocrine Response to Treadmill Exercise in 3xTg-AD Mice |
| Q34189447 | Gene-environment interaction research and transgenic mouse models of Alzheimer's disease |
| Q35113832 | Genetic Association between Akt1 Polymorphisms and Alzheimer's Disease in a Japanese Population |
| Q38256939 | Genetic risk factors: their function and comorbidities in Alzheimer's disease. |
| Q42748374 | Genetics and genomics of late-onset Alzheimer's disease and its endophenotypes |
| Q24629875 | Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways |
| Q35030388 | Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study |
| Q35852564 | Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics |
| Q35582469 | Glutamate-mediated primary somatosensory cortex excitability correlated with circulating copper and ceruloplasmin |
| Q39728463 | Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment |
| Q36063447 | Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target? |
| Q39802621 | Glycogen synthase kinase-3. |
| Q37883104 | Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease? |
| Q34143466 | Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy |
| Q35178436 | High Throughput ELISAs to Measure a Unique Glycan on Transferrin in Cerebrospinal Fluid: A Possible Extension toward Alzheimer's Disease Biomarker Development |
| Q34181363 | High-Dimensional Medial Lobe Morphometry: An Automated MRI Biomarker for the New AD Diagnostic Criteria. |
| Q35872213 | History, present, and progress of frontotemporal dementia in china: a systematic review |
| Q35884815 | Hormone replacement therapy and risk for neurodegenerative diseases. |
| Q41216426 | Hypothesis: soluble aβ oligomers in association with redox-active metal ions are the optimal generators of reactive oxygen species in Alzheimer's disease |
| Q33944771 | Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780. |
| Q59810560 | Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease |
| Q42726604 | Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to aβ Peptide-induced membrane changes |
| Q57115718 | Impaired Cerebral Vasomotor Reactivity in Alzheimer's Disease |
| Q35029378 | Improving the specificity of EEG for diagnosing Alzheimer's disease. |
| Q36729084 | In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects |
| Q92065340 | In Vivo Cognitive-Enhancing, Ex Vivo Malondialdehyde-Lowering Activities and Phytochemical Profiles of Aqueous and Methanolic Stem Bark Extracts of Piliostigma thonningii (Schum.). |
| Q42118376 | In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through? |
| Q35030119 | Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease |
| Q34461012 | Increased mRNA Levels of TCF7L2 and MYC of the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain |
| Q33894668 | Influence of water quality on cholesterol-induced tau pathology: preliminary data |
| Q35188012 | Inhibitory effects of sodium arsenite and acacia honey on acetylcholinesterase in rats |
| Q41811368 | Insight into glutamate excitotoxicity from synaptic zinc homeostasis |
| Q42082363 | Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases |
| Q34078381 | Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution |
| Q35030310 | Intracellular APP Domain Regulates Serine-Palmitoyl-CoA Transferase Expression and Is Affected in Alzheimer's Disease. |
| Q35418351 | Introducing Human APOE into Aβ Transgenic Mouse Models |
| Q34460764 | Iron and mechanisms of neurotoxicity |
| Q42055616 | Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? |
| Q28248217 | Issues raised involving the copper hypotheses in the causation of Alzheimer's disease |
| Q42160127 | Japanese Alzheimer's disease and other complex disorders diagnosis based on mitochondrial SNP haplogroups |
| Q35094383 | Joint assessment of structural, perfusion, and diffusion MRI in Alzheimer's disease and frontotemporal dementia |
| Q37448495 | KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients |
| Q24631994 | Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis |
| Q96134021 | Knowledge regarding Alzheimer's Disease among College Students of Kathmandu, Nepal |
| Q41776512 | Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease |
| Q42133275 | Lack of Correlation of WAIS Digit Span with Clox 1 and the Dementia Rating Scale in MCI |
| Q28385535 | Lead, manganese, and methylmercury as risk factors for neurobehavioral impairment in advanced age |
| Q40292339 | Leptin: a novel therapeutic target in Alzheimer's disease? |
| Q34043074 | Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease |
| Q36031983 | Lessons from tau-deficient mice |
| Q28307760 | Link between Aluminum and the Pathogenesis of Alzheimer's Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses |
| Q41604924 | Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes |
| Q36702181 | Longitudinal Changes in the Government-Certified Index Stage and Requisite Costs for Long-Term Care Insurance System among the Community-Dwelling Demented Elderly in Japan |
| Q38042636 | Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology |
| Q34924112 | MRI shows more severe hippocampal atrophy and shape deformation in hippocampal sclerosis than in Alzheimer's disease |
| Q34923627 | Magnetoencephalography as a putative biomarker for Alzheimer's disease |
| Q33581786 | Major Depressive Symptoms Increase 3-Year Mortality Rate in Patients with Mild Dementia |
| Q34952155 | Management of demented patients in emergency department |
| Q24600533 | May "mitochondrial eve" and mitochondrial haplogroups play a role in neurodegeneration and Alzheimer's disease? |
| Q41487372 | Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins |
| Q33467462 | Medical Students' Perceptions of Dementia after Participation in Poetry Workshop with People with Dementia |
| Q34416921 | Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value |
| Q35001051 | Melatonin in mitochondrial dysfunction and related disorders |
| Q34923956 | Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer's β-Amyloid Protein |
| Q42748314 | Memory Awareness Influences Everyday Decision Making Capacity about Medication Management in Alzheimer's Disease |
| Q42006882 | Memory complaints associated with seeking clinical care |
| Q41835175 | Metals and Alzheimer's disease. |
| Q34078507 | Methods to Enhance Verbal Communication between Individuals with Alzheimer's Disease and Their Formal and Informal Caregivers: A Systematic Review |
| Q39719620 | MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues |
| Q36031159 | MicroRNAs and the Regulation of Tau Metabolism |
| Q35986371 | Microglia in Alzheimer brain: a neuropathological perspective |
| Q36072124 | Microglia in Alzheimer's Disease: It's All About Context |
| Q58701591 | Microglia in Alzheimer's disease |
| Q42322507 | Microglia, Alzheimer's disease, and complement |
| Q35975429 | Microglial Amyloid-β1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease |
| Q35999547 | Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease |
| Q41815702 | Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation |
| Q38016165 | Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. |
| Q42250808 | Mild cognitive impairment: beyond memory dysfunction |
| Q34247588 | Mild cognitive impairment: statistical models of transition using longitudinal clinical data |
| Q30474134 | Mitochondria are related to synaptic pathology in Alzheimer's disease. |
| Q34922777 | Mitochondria, Amyloid β, and Alzheimer's Disease |
| Q37783538 | Mitochondria, Cognitive Impairment, and Alzheimer's Disease |
| Q34078241 | Modeling Presenilin-Dependent Familial Alzheimer's Disease: Emphasis on Presenilin Substrate-Mediated Signaling and Synaptic Function |
| Q39206398 | Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease |
| Q37976706 | Modelling tauopathies in Drosophila: insights from the fruit fly. |
| Q42286536 | Modulation of gamma-secretase for the treatment of Alzheimer's disease |
| Q36499901 | Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells |
| Q42792695 | Morphological Factor Estimation via High-Dimensional Reduction: Prediction of MCI Conversion to Probable AD. |
| Q41904833 | Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network |
| Q41861393 | Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease |
| Q28072312 | Nanoscale Extracellular Vesicle Analysis in Alzheimer's Disease Diagnosis and Therapy |
| Q41911149 | Neprilysin is poorly expressed in the prefrontal cortex of aged dogs with cognitive dysfunction syndrome |
| Q34924165 | Neuroimaging measures as endophenotypes in Alzheimer's disease |
| Q41486768 | Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease |
| Q37393152 | Neuroinflammation and copper in Alzheimer's disease. |
| Q34143859 | Neuroinflammation, AD, and Dementia |
| Q37783527 | Neuroinflammation, Microglia and Implications for Anti-Inflammatory Treatment in Alzheimer's Disease |
| Q34143614 | Neuron loss in transgenic mouse models of Alzheimer's disease |
| Q37780959 | Neuronal models for studying tau pathology. |
| Q35936632 | Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans |
| Q36045181 | Neuroprotection and neuroregeneration in Alzheimer's disease |
| Q34078125 | Neuroprotective Effects ofCentella asiaticaagainst Intracerebroventricular Colchicine-Induced Cognitive Impairment and Oxidative Stress |
| Q42958683 | Neuroprotective Role of a Novel Copper Chelator against Aβ 42 Induced Neurotoxicity |
| Q42556441 | Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress |
| Q34953672 | Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. |
| Q34244426 | New acetylcholinesterase inhibitors for Alzheimer's disease |
| Q34460501 | New proteins found interacting with brain metallothionein-3 are linked to secretion |
| Q38509496 | New thinking on the etiology and pathogenesis of late-onset Alzheimer's disease. |
| Q42728774 | Nonconvulsive seizures and dementia: a case report |
| Q37632344 | Novel Point Mutations and A8027G Polymorphism in Mitochondrial-DNA-Encoded Cytochrome c Oxidase II Gene in Mexican Patients with Probable Alzheimer Disease. |
| Q42133566 | Novel therapeutics in Alzheimer's disease |
| Q35993835 | Ocular manifestations of Alzheimer's disease in animal models. |
| Q53073171 | Oil Palm Phenolics Inhibit the In Vitro Aggregation of β-Amyloid Peptide into Oligomeric Complexes. |
| Q39728566 | On the involvement of copper binding to the N-terminus of the amyloid Beta Peptide of Alzheimer's disease: a computational study on model systems |
| Q26776178 | PET Imaging of Epigenetic Influences on Alzheimer's Disease |
| Q35226905 | Paradigm shift in treatment of Alzheimer's disease: zinc therapy now a conscientious choice for care of individual patients |
| Q34127547 | Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model |
| Q37825442 | Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease |
| Q91533358 | Physician Perceptions about the Barriers to Prompt Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease |
| Q64095373 | Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease |
| Q30370203 | Playing a Musical Instrument as a Protective Factor against Dementia and Cognitive Impairment: A Population-Based Twin Study |
| Q42199131 | Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases |
| Q38833738 | Potential peripheral biomarkers for the diagnosis of Alzheimer's disease |
| Q34077494 | Predictors of the Progression of Dementia Severity in Brazilian Patients with Alzheimer's Disease and Vascular Dementia |
| Q42263333 | Preferential selectivity of inhibitors with human tau protein kinase gsk3β elucidates their potential roles for off-target Alzheimer's therapy |
| Q34042415 | Prevention of dementia: focus on lifestyle |
| Q125361446 | Prognosis of Biomarker of Alzheimer’s Disease in the Function of the Retina and Secondary Molecular Structure Variation of the Retina and Brain |
| Q35895780 | Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence of APOE and TOMM40 on Brain Integrity |
| Q41597801 | Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders |
| Q41869540 | Protein kinase C-regulated aβ production and clearance |
| Q34283149 | Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease |
| Q33861527 | Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. |
| Q36140952 | Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment |
| Q34416770 | Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease |
| Q33720955 | Regional Cerebral Blood Flow in Mild Cognitive Impairment and Alzheimer's Disease Measured with Arterial Spin Labeling Magnetic Resonance Imaging |
| Q42102101 | Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3 |
| Q36090758 | Relative Preservation of Advanced Activities in Daily Living among Patients with Mild-to-Moderate Dementia in the Community and Overview of Support Provided by Family Caregivers |
| Q36200059 | Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. |
| Q42054888 | Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimer's disease |
| Q35895842 | Risk and Determinants of Dementia in Patients with Mild Cognitive Impairment and Brain Subcortical Vascular Changes: A Study of Clinical, Neuroimaging, and Biological Markers-The VMCI-Tuscany Study: Rationale, Design, and Methodology. |
| Q34077502 | Risk of Dementia Associated with Elevated Plasma Homocysteine in a Latin American Population |
| Q37316130 | Role of copper and cholesterol association in the neurodegenerative process |
| Q99551957 | Scopolamine-Induced Memory Impairment in Mice: Neuroprotective Effects of Carissa edulis (Forssk.) Valh (Apocynaceae) Aqueous Extract |
| Q47845914 | Seeking a New Paradigm for Alzheimer's Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease |
| Q33893279 | Sensitivity of nursing home cost comparisons to method of dementia diagnosis ascertainment |
| Q42768023 | Sensorimotor Cortex Reorganization in Alzheimer's Disease and Metal Dysfunction: A MEG Study |
| Q41866339 | Shilajit: a natural phytocomplex with potential procognitive activity |
| Q34291458 | Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease? |
| Q41841425 | Silencing of amyloid precursor protein expression using a new engineered delta ribozyme |
| Q35810686 | Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro |
| Q41960933 | Slowing and Loss of Complexity in Alzheimer's EEG: Two Sides of the Same Coin? |
| Q36128825 | Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models |
| Q35810855 | Specific EEG changes associated with atrophy of hippocampus in subjects with mild cognitive impairment and Alzheimer's disease. |
| Q42113874 | Specific Silencing of L392V PSEN1 Mutant Allele by RNA Interference |
| Q37556982 | Spectral Analysis of EEG in Familial Alzheimer's Disease with E280A Presenilin-1 Mutation Gene |
| Q34557355 | Spectroscopic Characterization of Intermolecular Interaction of Amyloid β Promoted on GM1 Micelles. |
| Q34078130 | Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis |
| Q34169857 | Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop |
| Q38000563 | Stimulation-dependent intraspinal microtubules and synaptic failure in Alzheimer's disease: a review |
| Q104143162 | Structural Brain Imaging Phenotypes of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Found by Hierarchical Clustering |
| Q34280787 | Structure and pathology of tau protein in Alzheimer disease |
| Q42591784 | Studies on interaction of buffalo brain cystatin with donepezil: an Alzheimer's drug |
| Q42177260 | Sweepers in the CNS: Microglial Migration and Phagocytosis in the Alzheimer Disease Pathogenesis |
| Q37980146 | Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease |
| Q37883102 | Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway. |
| Q42180899 | Tau Phosphorylation by GSK3 in Different Conditions |
| Q42151546 | Tau and caspase 3 as targets for neuroprotection |
| Q42320967 | Tau protein: function and pathology |
| Q36277794 | Test-retest reliability of a new medial temporal atrophy morphological metric |
| Q26740194 | The Acceptability and Usefulness of Cognitive Stimulation Therapy for Older Adults with Dementia: A Narrative Review |
| Q21296650 | The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? |
| Q34069203 | The Association between Apolipoprotein E Gene Polymorphism and Mild Cognitive Impairment among Different Ethnic Minority Groups in China |
| Q26864818 | The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton |
| Q38833255 | The Cellular Prion Protein Prevents Copper-Induced Inhibition of P2X(4) Receptors. |
| Q41980641 | The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction |
| Q90610440 | The Development and Psychometric Validation of a Comprehensive Measure Assessing Fear of Incompetence among Adults Who Have a Family Member with Dementia |
| Q57088502 | The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease |
| Q42401543 | The Effects of SIRT1 on Alzheimer's Disease Models |
| Q36246490 | The Impact of Experience with a Family Member with Alzheimer's Disease on Views about the Disease across Five Countries. |
| Q35029471 | The Link between Cognitive Measures and ADLs and IADL Functioning in Mild Alzheimer's: What Has Gender Got to Do with It? |
| Q36253619 | The Relation between Inflammation and Neuropsychological Test Performance |
| Q42175582 | The Relationship between Different Assays for Detection and Quantification of Amyloid Beta 42 in Human Cerebrospinal Fluid |
| Q42726631 | The Role of GSK3 in Presynaptic Function |
| Q41899169 | The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease? |
| Q28386834 | The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations |
| Q35978959 | The biphasic role of microglia in Alzheimer's disease |
| Q42119567 | The chick as a model for the study of the cellular mechanisms and potential therapies for Alzheimer's disease |
| Q42323216 | The contribution of the amyloid hypothesis to the understanding of Alzheimer's disease: a critical overview. |
| Q42791822 | The default mode network in healthy aging and Alzheimer's disease |
| Q36369315 | The needs of older people with mental health problems: a particular focus on dementia patients and their carers. |
| Q34572079 | The pathogenesis of Alzheimer's disease: a reevaluation of the "amyloid cascade hypothesis" |
| Q34512696 | The pathological roles of ganglioside metabolism in Alzheimer's disease: effects of gangliosides on neurogenesis |
| Q42934998 | The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease |
| Q41488419 | The role of zinc in Alzheimer's disease |
| Q42738256 | The use of auditory event-related potentials in Alzheimer's disease diagnosis |
| Q41887222 | The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease |
| Q34951844 | Thickness in entorhinal and subicular cortex predicts episodic memory decline in mild cognitive impairment. |
| Q42018800 | To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease |
| Q41985629 | Transcranial magnetic stimulation studies in Alzheimer's disease |
| Q42177253 | Traumatic brain injury, microglia, and Beta amyloid |
| Q36470109 | Trends in Alzheimer's disease and dementia in the asian-pacific region. |
| Q36336762 | Trends in prevalence and mortality of dementia in elderly Hong Kong population: projections, disease burden, and implications for long-term care. |
| Q36311294 | Trends in the prevalence of dementia in Japan |
| Q34077895 | Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future |
| Q39572889 | TrkB Isoforms Differentially Affect AICD Production through Their Intracellular Functional Domains. |
| Q30670280 | Utility of the mini-cog for detection of cognitive impairment in primary care: data from two spanish studies. |
| Q37960498 | Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications |
| Q42513498 | Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice |
| Q42155407 | Virtual screening and biological evaluation of piperazine derivatives as human acetylcholinesterase inhibitors. |
| Q26782403 | Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics |
| Q42102220 | Volumetric differences in mapped hippocampal regions correlate with increase of high alpha rhythm in Alzheimer's disease |
| Q35001234 | What Are the bona fide GSK3 Substrates? |
| Q36072517 | Will posttranslational modifications of brain proteins provide novel serological markers for dementias? |
| Q42729005 | Yeast as a model system to study tau biology. |
| Q38162228 | Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer's disease |
| Q34155662 | cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases |
| Q42530506 | α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies |
| Q40715930 | γ -Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? |
| Q42071699 | γ-Secretase Modulators: Can We Combine Potency with Safety? |
| Q38076426 | γ-Secretase-Dependent Proteolysis of Transmembrane Domain of Amyloid Precursor Protein: Successive Tri- and Tetrapeptide Release in Amyloid β-Protein Production |
Search more.